Table 4.
The univariate analysis and multivariate analysis for DFS.
| Parameters | Group | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P | HR | 95% CI | P | HR | 95% CI | ||||
| Low | High | Low | High | ||||||
| GRIm score | Low | 0.005 | 1(Ref.) | 0.008 | 1(Ref.) | ||||
| High | 2.891 | 1.382 | 6.047 | 2.789 | 1.304 | 5.965 | |||
| NLR | Low | 0.007 | 1(Ref.) | 0.004 | 1(Ref.) | ||||
| High | 2.288 | 1.250 | 4.188 | 2.500 | 1.349 | 4.636 | |||
| Age* | <51 | 0.743 | 1(Ref.) | ||||||
| ≥51 | 0.860 | 0.350 | 2.113 | ||||||
| BMI* | <23.8 | 0.534 | 1(Ref.) | ||||||
| ≥23.8 | 0.819 | 0.437 | 1.537 | ||||||
| Family history | No | 0.008 | 1(Ref.) | 0.015 | 1(Ref.) | ||||
| Yes | 2.435 | 1.265 | 4.687 | 1.964 | 1.137 | 3.391 | |||
| Basic disease | No | 0.015 | 1(Ref.) | 0.052 | 1(Ref.) | ||||
| Yes | 2.190 | 1.165 | 4.115 | 1.730 | 0.995 | 3.010 | |||
| Menarche age* | <15 | 0.131 | 1(Ref.) | ||||||
| ≥15 | 1.618 | 0.866 | 3.023 | ||||||
| Menopause | No | 0.000 | 1(Ref.) | 0.011 | 1(Ref.) | ||||
| Yes | 2.886 | 1.698 | 4.905 | 2.084 | 1.183 | 3.671 | |||
| ALT | <21 | 0.080 | 1(Ref.) | ||||||
| ≥21 | 2.327 | 0.905 | 5.982 | ||||||
| AST | <23 | 0.531 | 1(Ref.) | ||||||
| ≥23 | 0.805 | 0.408 | 1.588 | ||||||
| AST/ALT | <1.44 | 0.348 | 1(Ref.) | ||||||
| ≥1.44 | 1.445 | 0.669 | 3.121 | ||||||
| LDH | <170 | 0.850 | 1(Ref.) | ||||||
| ≥170 | 1.063 | 0.564 | 2.004 | ||||||
| ALB | <45 | 0.114 | 1(Ref.) | ||||||
| ≥45 | 0.623 | 0.347 | 1.120 | ||||||
| TBIL | <12.45 | 0.678 | 1(Ref.) | ||||||
| ≥12.45 | 1.139 | 0.615 | 2.111 | ||||||
| CA153 | <9.82 | 0.309 | 1(Ref.) | ||||||
| ≥9.82 | 1.373 | 0.746 | 2.526 | ||||||
| CEA | <1.49 | 0.203 | 1(Ref.) | ||||||
| ≥1.49 | 1.514 | 0.800 | 2.868 | ||||||
| D-D | <0.25 | 0.077 | 1(Ref.) | ||||||
| ≥0.25 | 0.594 | 0.333 | 1.058 | ||||||
| FBG | <2.6 | 0.984 | 1(Ref.) | ||||||
| ≥2.6 | 1.007 | 0.538 | 1.884 | ||||||
| White blood cell | <5.45 | 0.836 | 1(Ref.) | ||||||
| ≥5.45 | 0.906 | 0.356 | 2.306 | ||||||
| Neutrophil | <3.23 | 0.970 | 1(Ref.) | ||||||
| ≥3.23 | 0.982 | 0.375 | 2.571 | ||||||
| Lymphocyte | <1.70 | 0.514 | 1(Ref.) | ||||||
| ≥1.70 | 0.853 | 0.530 | 1.374 | ||||||
| Monocyte | <0.35 | 0.266 | 1(Ref.) | ||||||
| ≥0.35 | 0.691 | 0.360 | 1.325 | ||||||
| Platelet | <233 | 0.689 | 1(Ref.) | ||||||
| ≥233 | 0.877 | 0.460 | 1.670 | ||||||
| P Tumor size | ≤2 | 0.893 | 1(Ref.) | ||||||
| >2 and<5 | 0.866 | 1.062 | 0.527 | 2.139 | |||||
| ≥5 | 0.726 | 0.784 | 0.201 | 3.057 | |||||
| Pathological TNM Stage | I | 0.000 | 1(Ref.) | 0.000 | 1(Ref.) | ||||
| II | 0.104 | 2.251 | 0.847 | 5.982 | 0.370 | 1.401 | 0.670 | 2.932 | |
| III | 0.000 | 24.936 | 5.617 | 110.705 | 0.000 | 6.100 | 3.005 | 12.383 | |
| TALN | <14 | 0.674 | 1(Ref.) | ||||||
| ≥14 | 1.108 | 0.687 | 1.786 | ||||||
| PALN | <1 | 0.004 | 1(Ref.) | ||||||
| ≥1 | 2.053 | 1.253 | 3.365 | ||||||
| Molecular subtype | Luminal A | 0.345 | 1(Ref.) | ||||||
| Luminal B HER2+ | 0.103 | 3.258 | 0.786 | 13.498 | |||||
| Luminal B HER2- | 0.091 | 3.439 | 0.822 | 14.378 | |||||
| HER2 enriched | 0.391 | 2.064 | 0.394 | 10.811 | |||||
| Triple negative | 0.382 | 2.059 | 0.408 | 10.399 | |||||
| Chemotherapy | No | 0.000 | 1(Ref.) | 0.000 | 1(Ref.) | ||||
| Yes | 0.166 | 0.065 | 0.423 | 0.214 | 0.107 | 0.427 | |||
| Radiotherapy | No | 0.456 | 1(Ref.) | ||||||
| Yes | 0.736 | 0.328 | 1.650 | ||||||
| Endocrine therapy | No | 0.000 | 1(Ref.) | 0.000 | 1(Ref.) | ||||
| Yes | 0.178 | 0.069 | 0.461 | 0.241 | 0.137 | 0.423 | |||
| Targeted therapy | No | 0.814 | 1(Ref.) | ||||||
| Yes | 0.882 | 0.308 | 2.521 |
*Confounding factor. Abbreviation: DFS: disease free survival; GRIm score: Gustave Roussy Immune score; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; GGT: γ-glutamyl transpeptidase; ALB: albumin; TBIL: total bilirubin; DBIL: direct bilirubin; IBIL: indirect bilirubin; TP: total protein; G: globularproteins; PAB: prealbumin; CA153: cancer antigen 153; CEA: carcinoembryonic antigen; D-D: D-Dimer; FBG: fibrinogen; INR: international normalized ratio; NLR: neutrophil to lymphocyte ratio; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; E-cad: E-cadherin.